

Nye legemidler som ikke har markedsføringstillatelse

For legemidler oppført på listen gjelder retningslinjens vilkår uavhengig av indikasjon for bruken.

Oppdatert: 04.04.2024

Virkestoff	Indikasjon per nå. (Samt mulig andre indikasjoner i fremtiden.)	Orphan medicinal product (Se informasjon om COMP (Komiteen for legemidler mot sjeldne sykdommer) på www.legemiddelverket.no)	Oppført på listen
abicipar pegol	Treatment of neovascular (wet) age related macular degeneration (AMD)		aug.19
acalabrutinib	Treatment of mantel cell lymphoma - Kun denne indikasjonen		mar.18
acoramidis	Treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM)	x	mar.24
allogeneic bone marrow derived mesenchymal stromal cells, ex-vivo expanded	Treatment of graft-versus-host disease.	x	sep.23
alpelisib	Treatment of patients with severe manifestations of PIK3CArelated overgrowth spectrum - Kun denne indikasjonen	x	aug.22
apadamtase alfa	Treatment of congenital thrombotic thrombocytopenic purpura (cTTP) due to ADAMTS13 deficiency	x	jun.23
arimoclomol	Treatment of Niemann-Pick disease type C (NPC)	x	des.20
artesunate (*Kun styrken 60 mg)	Treatment of severe malaria	x	feb.21
aumolertinib	Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer		des.22

autologous human chondrocytes in vitro expanded	Repair of cartilage defects of the knee joint		sep.20
autologous cartilage-derived articular chondrocytes, in-vitro expanded	Repair of symptomatic, localised, full-thickness cartilage defects of the knee joint grade III or IV		jan.24
autologous glioma tumor cells, inactivated / autologous glioma tumor cell lysates, inactivated / allogeneic glioma tumor cells, inactivated / allogeneic glioma tumor cell lysates, inactivated	Treatment of glioma	x	okt.20
bardoxolone methyl	Treatment of chronic kidney disease (CKD)	x	okt.21 /des.21
belinostat	Relapserad/refraktært T-cellslymfom		mar.24
belumosudil	versus host disease (GvHD)		nov.22
beremagene-geperpavec	Treatment of patients from birth with dystrophic	x	des.23 /jun.23
belzutifan	Treatment of adult patients with advanced renal		jan.24
bevacizumab	Treatment of neovascular (wet) age related macular degeneration (nAMD) - Kun denne indikasjonen		feb.23
capivasertib	Indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (defined as IHC 0 or 1+, or IHC 2+/ISH-) locally advanced or metastatic breast cancer following recurrence or progression on or after an endocrine based regimen		jun.23

concizumab	Indicated for routine prophylaxis to prevent or reduce the frequency of bleeding in patients with - haemophilia A (congenital factor VIII deficiency) with FVIII inhibitors \geq 12 years of age.- haemophilia B (congenital factor IX deficiency) with FIX inhibitors of any age.		feb.23
copanlisib	Treatment of non-hodgkin lymphoma		mar.18
copanlisib	Treatment of adult patients with marginal zone lymphoma	x	jul.22
crovalimab	Treatment of paroxysmal nocturnal haemoglobinuria		aug.23
danicopan	Treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria	x	apr.23
daprodustat	Treatment of anemia associated with chronic kidney disease (CKD) in adults		apr.22
Datopotamab	Treatment of adult patients with locally advanced or metastatic non squamous nonsmall cell lung cancer (NSCLC)		apr.24
deferiprone	Treatment of neurodegeneration with brain iron accumulation - Kun denne indikasjonen	x	jun.19
delandistrogene moxeparovec	Treatment of Duchenne muscular dystrophy		aug.23
depatuximab mafodotin	Treatment of glioblastoma (GBM)		nov.18
diclofenamide	Treatment of periodic paralysis		feb.19
Diflunisal	Treatment of ATTR amyloidosis	x	mar.24
duvelisib	Treatment of adult patients with small lymphocytic lymphoma (SLL) - Kun denne indikasjonen	x	feb.20
edaravone	Amyotrophic lateral sclerosis (ALS)		jan.18
efanesoctocog alfa	Treatment and prophylaxis of bleeding in patients with haemophilia A		jun.23
eflornithine / sulindac	Treatment of familial adenomatous polyposis	x	jul.20
elafibranor	Treatment of primary biliary cholangitis (PBC)	x	nov.23
enasidenib	Treatment of acute myeloid leukaemia		mar.18
entolimod	Treatment of acute radiation syndrome	x	nov.17

eplontersen	Treatment of adult patients with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (ATTRv)	x	nov.23
erdafitinib	Treatment of adults with locally advanced or metastatic urothelial carcinoma		nov.19, nov.23
ferumoxytol	Intravenous treatment of iron deficiency anaemia (IDA)		jun.22
fidanacogene elaparvovec	Indicated for the treatment of severe and moderately severe haemophilia B	x	jun.23
fruquintinib	Treatment of metastatic colorectal cancer		jul.23
garadacimab	Routine prevention of attacks of hereditary angioedema (HAE)	x	des.23
glutamine	Treatment of sickle cell disease		mar.18
govorestat	Treatment of adults and children aged 2 years and older with a confirmed diagnosis of classic galactosemia	x	jan.24
idebenone	Treatment of respiratory dysfunction in patients with Duchenne muscular dystrophy (DMD) not using glucocorticoids - Kun denne indikasjonen	x	aug.19
imetelstat	Treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts	x	nov.23
infigratinib	Treatment of cholangiocarcinoma	x	des.21
ipatasertib	Treatment of breastcancer		mar.18
iptacopan	Treatment of Paroxysmal Nocturnal Haemoglobinuria (PNH)		mai.23
lazertinib	Treatment of adult patients with advanced nonsmall cell lung cancer (NSCLC)		mar.24
lecanemab	Indicated as a disease modifying treatment in adult patients with Mild Cognitive Impairment due to Alzheimer's disease and Mild Alzheimer's disease (Early Alzheimer's disease)		feb.23

lenadogene nolparvovec	Treatment of vision loss due to Leber Hereditary Optic Neuropathy (LHON)	x	nov.20
leniolisib	Treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)	x	nov.22
linvoseltamab	Monotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma		mar.24
LUT014	Topical BRAF Inhibitor Therapy for EGFR Inhibitor–Induced Acneiform Rash		nov.23
macitentan / Tadalafil (kun denne spesifikk kombinasjon)	treatment of pulmonary arterial hypertension (PAH) in adult patients		aug.23
marstacimab	Indicated for routine prophylaxis of bleeding episodes in patients with haemophilia A or haemophilia B	x	nov.23
mirvetuximab soravtansine	Treatment of ovarian, fallopian tube, or primary peritoneal cancer	x	nov.23
mobocertinib	Treatment of adult patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).		jan.21
naporafenib	Treatment of advanced solid tumours including ovarian cancer		okt.21
nemolizumab	Treatment of moderate-to-severe atopic dermatitis and for the treatment of prurigo nodularis		mar.24
nirogacestat	Treatment of desmoid tumours	x	apr.24
odevixibat	Treatment of cholestatic pruritus in Alagille syndrome (ALGS) Kun denne indikasjonen		jan.24
obeticholic acid	Improvement of liver fibrosis and resolution of steatohepatitis in adult patients with significant liver fibrosis due to nonalcoholic steatohepatitis (NASH). Kun denne indikasjonen		aug.20
omadacycline tosylate	Treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in adults		okt.18

omecamtiv mecarbil	Treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction less than 30%		feb.23
oportuzumab monatox	Treatment and prevention of recurrence of carcinoma-in-situ (CIS) of the urinary bladder and prevention of recurrence of high grade Ta and/or T1 papillary tumours		apr.21
parsaclisib	Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL)	x	feb.22
pegcetacoplan	Treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) - Kun denne indikasjonen	x	feb.23
pevonedistat	Higher-risk chronic myelomonocytic leukemia (HR-CMML), low-blast acute myeloid leukemia (LB-AML) and higher risk myelodysplastic syndromes		aug.20
plazomicin	Treatment of symptomatic tenosynovial giant cell tumor (TGCT), also known as pigmented villonodular synovitis (PVNS) and giant cell tumor of the tendon sheath (GCT-TS), where surgical resection is potentially associated with worsening functional limitation or severe morbidity	x	mar.19
plazomicin	Treatment of Complicated urinary tract infection (cUTI), including pyelonephritis; treatment of Bloodstream infection (BSI); treatment of infections due to Enterobacteriaceae		nov.18
polihexanide	For the treatment of acanthamoeba keratitis	x	jun.22
repotrectinib	Treatment of ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) and for solid tumours; ROS1+ Advanced Non-Small Cell Lung Cancer (NSCLC) or NTRK+ Advanced Solid Tumors		jan.24, nov.21

resmetirom	Treatment of adults with nonalcoholic steatohepatitis (NASH)/metabolic dysfunction associated steatohepatitis (MASH) with liver fibrosis		apr.24
resminostat	Treatment of patients with advanced stage mycosis fungoides (MF) and Sézary syndrome (SS)		apr.24
retifanlimab	Treatment of locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) who have progressed on or who are intolerant of platinum	x	mar.21
retifanlimab	Treatment of Merkel cell carcinoma (MCC).	x	apr.23
romidepsin	Treatment of peripheral T-cell lymphoma (PTCL) in adult patients who have received at least one prior therapy.		feb.22
rovalpituzumab tesirine	Small cell lung cancer (SCLC)		jan.18
savolitinib	monotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma		mar.23
Seladelparlysindihydrat	A peroxisome proliferator receptor delta (PPAR δ) activator indicated for the treatment of primary biliary cholangitis (PBC) including pruritus in adults without cirrhosis or with compensated cirrhosis (Child-Pugh A) in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.		apr.24
serplulimab	First-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)	x	apr.23
sipavibart	Pre-eksponeringsprofylakse mot covid-19-sykdom hos spesielt sårbare grupper hvor vaksinasjon ikke gir tilstrekkelig beskyttelse mot alvorlig sykdom.		mar.24
siponimod	Indicated for the treatment of thrombocytopenia - Kun denne indikasjonen		okt.18
sodium phenylbutyrate/ ursodoxicoltaurine	Treatment of amyotrophic lateral sclerosis (ALS)	x	apr.22

sotatercept	Treatment of pulmonary arterial hypertension in adults	x	sep.23
sugemalimab	Treatment of non-small cell lung cancer (NSCLC)		mar.23
surufatinib	Treatment of progressive neuroendocrine tumours		jul.21
tazemetostat	Treatment of malignant mesothelioma and Epithelioid sarcoma		mai.21
tiratricol	Treatment of monocarboxylate transporter 8 (MCT8) deficiency	x	nov.23
tisotumab vedotin	treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy		mar.24
tofersen	Amyotrophic lateral sclerosis (ALS), Treatment of adults with amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1		nov.21, des.22
toripalimab	Combination treatment for metastatic or recurrent locally advanced nasopharyngeal carcinoma and for metastatic or recurrent oesophageal		des.22
trastuzumab duocarmazine	Treatment of HER2 (Human Epidermal Growth Factor Receptor 2)-positive metastatic breast		aug.22
troriluzole	Treatment of adult patients with spinocerebellar ataxia genotype 3 (SCA3)	x	nov.23
valemetostat	Ved tilbakevendende/refraktær (R/R) adult T-cell leukemia/lymphoma (ATLL).		apr.22
veliparib	Treatment of BRCA 1, BRCA 2, BARD1 and/or PALB2 mutated cancer		mar.18
zolbetuximab	Treatment of locally advanced unresectable or metastatic HER2 negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma	x	aug.23